Brendan D. Curti, M.D., from the Earle A. Chiles Research Institute of Providence Cancer Center in Portland, Oregon presented findings from his study at the 2017 AACR Annual Meeting that suggests the introduction of a virus to an antibody may be able to assist an existing immunotherapy treatment.


The virus, CVA21, when added to Yervoy, affects the cancerous cells in a way that makes them more vulnerable to the immunotherapy. From the small 22 person study, 4 people showed a complete response and 7 showed a partial response for a 50% overall response rate.


Because the study held promising results, it has been approved for an increased number of participants to gather more data. Hopefully Dr. Curti’s study will continue to bring positive findings and it can soon be used as a viable option for treatment.


The full article is available at: Cure – Virus to boost Immunotherapy


#RichardDavidKannMelanomaFoundation #RDKMelanomaFoundation #RDK #SunSmart #SunSmartAmerica #SunSaftey #SunSafe #RAY #Melanoma #AACR #Virus #Immunotherapy #EarleAChilesResearchInstitute